Technical Analysis for INO - Inovio Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 8.91 | -3.05% | -0.28 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical INO trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Hammer Candlestick | Bullish | -3.05% | |
Lizard Bullish | Bullish Day Trade Setup | -3.05% | |
Doji - Bullish? | Reversal | -3.05% | |
Lower Bollinger Band Walk | Weakness | -3.05% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Lizard Bullish Entry | about 12 hours ago | |
Hammer Candlestick Entry | about 12 hours ago | |
Rose Above Previous Day's High | about 12 hours ago | |
Up 2% | about 12 hours ago | |
Up 1% | about 12 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/01/2021
Inovio Pharmaceuticals, Inc. Description
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Infectious Diseases Cancers Prostate Cancer Clinical Research Influenza Coronavirus Hepatitis B Vaccine Vaccination Leukemia Novi Hepatitis C Immunodeficiency Hepatitis B Virus Hepatitis C Virus Influenza Vaccine Virus Malaria Papillomavirus Virology Cervical Cancer Avian Influenza Electroporation Seasonal/Pandemic Influenza Universal Flu Vaccine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 33.79 |
52 Week Low | 5.13 |
Average Volume | 16,842,430 |
200-Day Moving Average | 13.94 |
50-Day Moving Average | 11.18 |
20-Day Moving Average | 12.12 |
10-Day Moving Average | 10.47 |
Average True Range | 1.28 |
ADX | 27.02 |
+DI | 19.72 |
-DI | 27.86 |
Chandelier Exit (Long, 3 ATRs ) | 12.24 |
Chandelier Exit (Short, 3 ATRs ) | 12.25 |
Upper Bollinger Band | 15.93 |
Lower Bollinger Band | 8.31 |
Percent B (%b) | 0.08 |
BandWidth | 62.87 |
MACD Line | -0.75 |
MACD Signal Line | -0.21 |
MACD Histogram | -0.5397 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.75 | ||||
Resistance 3 (R3) | 9.83 | 9.64 | 9.61 | ||
Resistance 2 (R2) | 9.64 | 9.42 | 9.59 | 9.56 | |
Resistance 1 (R1) | 9.27 | 9.29 | 9.18 | 9.19 | 9.51 |
Pivot Point | 9.08 | 9.08 | 9.03 | 9.04 | 9.08 |
Support 1 (S1) | 8.71 | 8.86 | 8.62 | 8.63 | 8.31 |
Support 2 (S2) | 8.52 | 8.73 | 8.48 | 8.26 | |
Support 3 (S3) | 8.16 | 8.52 | 8.21 | ||
Support 4 (S4) | 8.07 |